Related Experiment Videos

Pharmacokinetic evaluation of cimetidine in newborn infants

Clinical Therapeutics
|January 1, 1985
PubMed

Insights

Cimetidine pharmacokinetics in neonates show that a dose of 5 to 7 mg/kg effectively suppresses gastric acid. This study analyzed drug concentrations and half-life in newborn infants with reflux esophagitis or stress ulcer.

Area of Science:

  • Neonatal pharmacology
  • Gastroenterology
  • Drug metabolism

Background:

  • Reflux esophagitis and stress ulcers are common in neonates.
  • Gastric acid suppression is crucial for managing these conditions in newborns.

Purpose of the Study:

  • To investigate the pharmacokinetics of cimetidine in newborn infants.
  • To determine appropriate dosing for effective gastric acid suppression in neonates.

Main Methods:

  • Studied three newborn infants with reflux esophagitis or stress ulcer.
  • Administered cimetidine intravenously (5 mg/kg and 10 mg/kg) and orally (10 mg).
  • Measured serum drug concentrations and calculated half-life.

Main Results:

  • Serum concentrations varied based on dosage and administration route.
  • Effective concentrations (>0.5 micrograms/ml) were maintained for several hours.
  • Drug half-life ranged from 1.10 to 2.18 hours.

Conclusions:

  • Preliminary data suggest 5 to 7 mg/kg cimetidine is effective for gastric acid suppression in neonates.
  • Further pharmacokinetic studies are warranted to confirm optimal dosing in this population.

Related Concept Videos